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 Abstract	
Residency at high altitude (HA) demands adaptation to challenging environmental conditions 
with hypobaric hypoxia being the most important one. Epidemiological and experimental data 
suggest that chronic exposure to HA reduces cancer mortality and lowers prevalence of 
metabolic disorders like diabetes and obesity implying that adaption to HA modifies a broad 
spectrum of physiological, metabolic and cellular programs with a generally beneficial 
outcome for humans. However, the complexity of multiple, potentially tumor-suppressive 
pathways at HA impedes the understanding of mechanisms leading to reduced cancer 
mortality. Many adaptive processes at HA are tightly interconnected and thus it cannot be 
ruled out that the entirety or at least some of the HA-related alterations act in concert to 
reduce cancer mortality. In this review we discuss tumor formation as a concept of 
competition between healthy and cancer cells with improved fitness – and therefore higher 
competitiveness – of healthy cells at high altitude. We discuss HA-related changes in glucose, 
lipid and iron metabolism that may have an impact on tumorigenesis. Additionally, we discuss 
two parameters with a strong impact on tumorigenesis, namely drug metabolism and physical 
activity, to underpin their potential contribution to HA-dependent reduced cancer mortality. 
Future studies are needed to unravel why cancer mortality is reduced at HA and how this 
knowledge might be used to prevent and to treat cancer patients.	
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1 Introduction	
Humans living at moderate (above 1500 m) and high (above 2500 m) altitude (HA) are 
chronically exposed to hypobaric hypoxia and need to adapt to this environmental challenge. 
The altitude-dependent drop in barometric pressure and subsequent decrease of the ambient 
partial pressure causes hypoxemia and tissue hypoxia. When sojourners acclimatize, their 
bodies respond first with short-term adaptations (hours to days; e.g. increased basal 
ventilation [1], plasma volume reduction [2, 3]) and later with long-term adaptations (weeks to 
months; e.g. increased erythropoiesis [4]) that are mainly driven by tissue hypoxia. The 
magnitude of response to HA is the key factor for physiological adaption or pathological mal-
adaption, the latter resulting in hypoxia-related altitude illnesses [5-7]. The cellular response 
to hypoxia is driven by hypoxia inducible transcription factors (HIF) that are rapidly activated 
when intracellular oxygen levels decline [8-10]. Iron-dependent prolyl-hydroxylases (PHDs) 
regulate the stability of HIF-α subunits resulting in either protein degradation when oxygen is 
sufficiently available or stabilization when oxygen supply is low [11]. The detailed regulation of 
HIFs by oxygen availability and their down stream targets have been extensively reviewed 
[11-13]. During oxygen deficiency, hematopoiesis is driven by the renal hormone 
erythropoietin (Epo) that is oxygen-dependently regulated by HIF-2 [14] and promotes red 
blood cell production. 
Epidemiological studies provide evidence that humans populating high altitude environments 
show reduced cancer mortality. Several possible explanations have been discussed in the 
past including elevated vitamin D synthesis due to higher background radiation [15]. However, 
the most adaptive processes at HA occur in response to reduced oxygen availability and this 
might be a much greater factor in cancer mortality. At the first glance, the observation of 
oxygen-dependent reduced cancer mortality at HA is counterintuitive because tumor hypoxia 
per se is rather a supportive factor for tumor growth and the development of aggressive 
phenotypes [16, 17]. Both hypoxia-inducible factors 1 and 2 (HIF-1/2) have been reported to 
promote tumor growth and metastasis [18-20]. In contrast, some studies show that the loss of 
HIF-1α expression promotes kidney cancer [21] suggesting that at least in some tissues 
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stabilized HIF is tumor suppressive. Recent studies analyzed evolutionary selected variants 
EGLN1 (encoding for PHD2) and EPAS1 (encoding for HIF-2α) genes in Tibetans and 
reported association of these variants with increased lung [22] and gastric [23] cancer risk. 
These HA-adapted variants of EGLN1 with D4E and C127S polymorphisms increased PHD2 
activity and promote HIF-α degradation [24, 25] suggesting that HIF stabilization at HA might 
contribute to reduced incidence/mortality of at least some types of cancer. In this review we 
briefly summarize the results of epidemiological and animal studies and discuss mainly 
oxygen-based mechanisms that may account for reduced cancer mortality. It should be 
mentioned that “mortality” is a clinical relevant outcome but does not further explain at which 
steps during the course of cancer disease (incidence, progression, dissemination, response 
to therapy) exposure to HA has affected and altered. 
2 Epidemiology	
2.1 Human	Studies	
In 1974/75 an inverse relationship of HA and leukemia cancer mortality in humans was 
reported for the first time [26-28]. These studies were followed by additional studies within the 
last decades that considered potential cofounders (such as environment and socio-economic 
status) and confirmed these findings [29-35]. Although overall cancer mortality negatively 
correlates with HA [31], site-specific cancer seem to respond differently to HA. While 
lymphoma, breast [36], lung, cancers of tongue and mouth or larynx [29, 35] display reduced 
mortality at HA, liver and cervix mortality showed no difference between low and high altitude. 
As expected, mortality from melanoma was increased due to the higher background radiation 
[37]. Very recently, it has been shown that highlanders display a reduced incidence of lung 
and breast cancer [38] supporting earlier observations that HA is indeed involved in 
prevention of tumorigenesis. 
2.2 Animal	Studies	
Reduced cancer mortality at HA is not unique to humans but has been observed in mice 
exposed to very high altitude (4540 m) for a prolonged period of time after exposure to sub-
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lethal levels of x-rays resulting in reduced incidence of tumor formation [39]. Additionally, the 
incidence of spontaneous leukemia is reduced at HA [40] but spontaneously forming 
pulmonary tumors display a higher incidence at HA [41]. Back in the 1980s, studies in several 
rat and mouse tumor models demonstrated reduced primary tumor growth and metastatic 
spread as well as improved response to therapeutic treatment at HA [42-44]. A more recent 
study showed reduced tumor incidence not only in two spontaneously developing tumor 
mouse models, namely p53-/- and APCMin/+, but also in a chemically induced skin cancer 
model in mice exposed to 10% normobaric oxygen [45] corresponding to an extreme altitude 
of approximately 5500 – 6000 meter above sea level [12]. With their experimental setup, the 
latter authors prove that reduced oxygen levels protect from oncogenic events and 
tumorigenesis matching the epidemiological findings of Simeonov and Himmelstein [38]. 
3 Cancer	and	Adaptation	
Theoretically, cancer cells can be considered to be evolutionary selected cell lineages that 
have escaped control of replication and cell death and meet the traditional characteristics of 
minimal Darwinian populations, namely variation, selection and inheritance [46]. As a 
consequence, the evolutionary process of tumor formation, progression and metastasis 
depends on the nature of the niche that is populated by cancer cells and their ability to 
compete for resources with healthy cells within the same niche. Natural selection demands 
genotypes that differ in fitness to result in improved reproduction success. Although 
oncogenic events are commonly assumed to increase cellular fitness, DeGregori, (2011) 
suggests a model of adaptive oncogenesis, in which genetic variations rarely result in 
advantageous traits in healthy (and young) populations of (stem) cells, since they always 
display a high degree of fitness to maintain tissue integrity and this successfully competes 
against somatic cancer cell evolution [47]. Cell age and/or damaging insults reduce cellular 
fitness and change the adaptive landscape due to accumulation of mutations and alterations 
in the microenvironment, both promoting selection of adaptive oncogenesis events [47]. An 
example in relation to cancer at HA is melanoma that is increased due to increased radiation 
exposure [37] resulting in increased damage of epidermal cells and consequently the 
reduction in cell fitness. In the light of this hypothesis, we discuss below reduced cancer 
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mortality and incidence at HA as a competitive mechanism between cancer and healthy cells. 
We suggest that HA increases fitness of healthy cells and/or modifies the tumor 
microenvironment resulting in adverse conditions for tumor cell development and expansion. 
Other diseases (e.g. stroke and cardiovascular diseases) display also a link between high 
altitude and reduced mortality [48] supporting our assumption. As a matter of fact, the 
metabolic syndrome, diabetes type 2 and obesity are cancer risk factors [49, 50] and have a 
lower prevalence in humans populating elevated areas [51-53]. In the next sections, we 
consider cell biological and metabolic alterations at HA that might pose a bottleneck for 
emerging tumors in humans living at higher elevations. 
3.1 Metabolic	Alterations	
3.1.1 Glucose	and	Glutamine	Metabolism	
The competition for nutrition in a resource-restricted environment may result in different 
metabolic pathways being susceptible to alterations that might occur at HA. The most 
prominent metabolic reprogramming in tumor cells is the “Warburg effect” resulting in aerobic 
metabolism of glucose and increased lactate production – even when sufficient oxygen is 
available [54]. A recent review summarizing tumor metabolism and discussing metabolites 
that limit tumor progression as potential therapeutic targets suggested that neither ATP nor 
NADPH may limit tumor proliferation [54]. However, restoration of tricarboxylic acid (TCA) 
cycle metabolites and the synthesis of nucleotides may be a limiting factor in tumor 
progression due to the high demand for DNA synthesis in proliferating cells. Glucose and/or 
glutamine (depending on tumor type and microenvironment) refuel the TCA cycle and provide 
substrates for the nucleotide metabolism [55, 56]. Consequently, both, glucose and glutamine 
may limit tumor progression when insufficiently supplied to cancer cells (e.g. when healthy 
cells increase their demand, or when less substrate is provided from blood). As expected, 
hyperglycemia correlates with an increased risk of tumorigenesis [57] and because 
highlanders have reduced plasma glucose and glutamine concentrations (at least in acute 
and prolonged exposure to HA [58, 59]) this restriction possibly contributes to reduced cancer 
mortality [58, 60]. Blood glucose levels are mainly controlled by the liver and partially by 
kidneys [61, 62] and release of hepatic glucose is stimulated by glucagon, fatty acids and 
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catecholamines but suppressed by insulin [61]. Accordingly, as Andean highlanders display 
higher glucagonemia and lower glycemia, their exposure to HA might reduce hepatic 
glucagon sensitivity resulting in reduced glucose release from the liver. In cancer cells, HIF-1 
increases the expression levels of glucose transporter 1 and 3 (GLUT1/3) to facilitate glucose 
uptake [63]. However, adipocytes respond similarly to hypoxia with increased GLUT1/3 
expression levels [64]. Furthermore, acclimatization to HA increases the uptake and 
metabolism of blood glucose by human skeletal and heart muscle [61], facilitated by a 
hypoxia-driven increase in HIF-1 as well as GLUT4 expression levels in human muscle cells 
[61, 65].  
In conclusion, cancer cells are competing with healthy cells and tissues (e.g. muscles) for 
nutrition including glucose and glutamine and exposure to HA possibly limits the availability 
(reduced plasma levels) and increases glucose uptake and metabolism in healthy tissue 
(competition) for these metabolites. However, metabolic pathways are intricately 
interconnected and many cancer cells utilize a broad spectrum of metabolites including lipids, 
lactate and further amino acids [54] potentially compensating reduced availability of even 
central substrates like glucose. 
3.1.2 Lipid	Metabolism	
Lipid metabolism is a complex process that is regulated by multiple pathways to control 
uptake, transport, metabolism and synthesis. In turn, lipids also differentially regulate cellular 
signaling transduction and pathways [66]. The cell membrane, mainly consisting of lipids, 
contains lipid rafts that are spatial membrane assemblies of cholesterol and derivatives 
providing a platform for signaling transduction processes involved in apoptosis [67] as well as 
cell survival and proliferation [68, 69]. Small variations in the tightly regulated metabolism of 
lipids result in disturbed energy homeostasis ultimately leading to fat accumulation, increased 
body mass and obesity, which are risk factors for breast [70], colon [71], kidney [72], prostate 
[73], gallbladder [74] and pancreas cancer [75]. Fast growing tumors display dysregulated 
lipid homeostasis with reduced 3-hydroxy-3-methyl-glutaryl CoA (HMG-CoA) reductase and 
low-density lipoprotein (LDL) receptor activity as well as cholesterol enrichment in tumor cells 
[76]. Cancer cells require energy as well as metabolic precursors for cell proliferation 
associated with rapid lipid synthesis for assembling membranes of new cells. Lipids are 
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provided from external sources as well as intracellularly by fatty acid synthesis [76] and 
regulate, besides membrane assembly, the cancer related pathways PI3K/AKT/mTOR, RAS 
and Wnt [76-78]. Further, free fatty acids in human plasma are also involved in insulin 
resistance [79] resulting in high insulin and insulin-like growth factors (IGF) that directly 
promote tumor progression [73, 76]. The lipid profile of tumors in patients at HA has not been 
published, but hypoxia has been shown to facilitate exogenous lipid uptake of cancer cells [80, 
81]. Such a lipid supply might be suppressed in highlanders who have been reported to 
exhibit lower fatty acid plasma levels [61] and potentially decrease fatty acid metabolism due 
to SIRT4 induction [82]. Elevated lipid levels are commonly accepted to be severe risk factors 
for cancer [83, 84]. Highlanders living at moderate altitude (1500 m) have reduced levels of 
total cholesterol and triglycerides but an increase of high density lipoprotein (HDL) [85, 86] 
that correlates with reduced prevalence of both cardiovascular diseases [87, 88] and cancer 
incidence including breast [89], prostate [90, 91] and potentially colon cancer, as shown in 
mice [92]. Collectively, the restricted lipid metabolism at HA might be shifted against the 
development and progression of tumors. 
3.1.3 Iron	Metabolism	and	Anemia	of	Cancer	
Iron is an essential nutrient involved in the formation of red blood cells, in many oxidation-
reduction processes within the organism as well as in energy metabolism, mitochondrial 
respiration, and DNA synthesis. Iron metabolism is controlled on both the systemic and 
cellular levels. The liver hormone hepcidin is a key regulator for iron homeostasis inhibiting 
intestinal iron absorption as well as macrophage release by degrading the iron-transport 
protein ferroportin (Fpn1) [93-95]. Hypoxia is tightly associated with iron metabolism. HIFs 
control directly or indirectly the expression of the divalent metal transporter 1 (DMT-1) and 
Fpn1 among others [96, 97] and iron is an essential cofactor for PHDs that catalyze the 
hydroxylation of HIF-α subunits to target them for degradation [11-13]. Under hypoxic 
conditions hepcidin mRNA transcription is indirectly inhibited by Epo via erythroferrone [96, 
98] to guarantee sufficient iron supply for red blood cell formation. Cancer cells have a higher 
iron demand and thus elevated iron uptake. Correspondingly, high iron levels have been 
determined as a risk factor for cancer [99-101] with an impact on tumor-associated 
macrophages and the tumor microenvironment [102]. Cancer cells display disturbed iron 
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homeostasis with increased expression of transferrin receptor 1 (uptake) [103], decreased 
expression of ferritin (storage) [104, 105] and inhibition of ferroportin (release) [106]. 
Exposure to HA demands increased hematopoiesis to cope with reduced oxygen uptake and 
thus is associated with elevated iron utilization for red blood cell formation [96]. At very high 
altitudes female adults develop reduced body iron levels [107] potentially decreasing the risk 
for tumor incidence. Acute or short-term exposure to HA decreases plasma iron levels, ferritin 
and transferrin saturation depending on the dietary iron intake [108, 109]. The critical role of 
iron in malignancy has been demonstrated by use of iron chelators that sequester iron or by 
applying antibodies against the transferrin receptor 1 [110-112]. Both approaches inhibit 
cancer progression. Iron deficiency is the most prevalent nutritional disorder [113] resulting in 
anemia. This includes anemia of cancer [114] that frequently occurs in patients secondary to 
their cancer [114] or is induced during chemo and/or radiotherapy [115, 116]. Anemia of 
cancer reduces quality of life and is a poor prognostic factor in cancer patients [117, 118]. 
Consequently, it demands treatment that is currently achieved by iron supplementation, 
administration of erythropoiesis-stimulating agents (ESA) and blood transfusion [114]. 
Hepcidin expression (the aforementioned key regulator of iron homeostasis) is frequently 
induced in tumor patients by cancer-induced inflammatory signals [119] and prevents iron 
uptake resulting in iron deficiency and finally anemia. Interestingly, hepcidin levels – at least 
during acute and prolonged exposure to HA and isobaric hypoxia – decline to meet the 
increased iron demand [120-123]. Epidemiological data on hepcidin expression levels and 
anemia of cancer in highlanders are missing and, consequently, thorough reports on 
frequency, severity and treatment success are required to determine its role in cancer 
mortality at HA. It has been reported, however, that the frequency of end-stage renal disease 
dependent anemia (which can occur in cancer patients as a result of renal tumor invasion 
[114]) is reduced [124, 125]. Additionally, the response to Epo or erythropoiesis-stimulating 
agents (ESA) is improved at HA [126, 127]. Besides iron deficiency, impaired Epo production 
(due to cancer- or therapy-induced kidney damage) is the major cause for anemia of cancer 
[114]. With increasing altitude the number of end-stage renal disease patients receiving ESA 
as well as the required dosages surprisingly are lower while hemoglobin levels as well as 
patient survival are higher [126, 127]. The reduced requirement of ESA treatment in anemic 
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patients at HA may also have implications for cancer mortality. Several clinical [128-135] and 
preclinical [136-144] studies suggest that ESA treatment in cancer patients actually reduces 
patient survival by promoting tumor growth via binding to Epo receptors on many cancer cell 
types. Hence, the FDA has lowered the minimally accepted hemoglobin levels in anemic 
cancer patients (lowlanders) to <12 g/dl [145, 146]. A potentially lower demand of ESA to treat 
anemia of cancer at HA might thus contribute to reduced cancer mortality at HA. 
3.2 Pharmacokinetics	and	Pharmacodynamics	at	HA	
A frequently ignored subject is the alteration of drug metabolism at HA. In addition to surgery 
and irradiation, chemotherapy is the most frequent choice of treatment in cancer. The 
pharmacokinetic and pharmacodynamic responses to drugs have been poorly studied in 
highlanders [147]. With respect to the approximately 400 million humans living at elevated 
areas (above 1500 m) [48, 148], this population is considerably underrepresented, especially 
because there is clear evidence that HA exposure (like all other physiological stress 
conditions) has impact on drug absorption, distribution, metabolism and detoxification and 
clearance [147]. Different types of chemotherapy used to treat cancer include alkylating 
agents, antimetabolites, anti-microtubule agents, topoisomerase inhibitors, antibiotics, and 
antibodies and all may have a potentially altered efficacy at HA. Anthracyclines (e.g. 
doxorubicin) or alkylating agents (cisplatin) generate high levels of reactive oxygen species 
(ROS) that have an impact on cancer cells [149]. Since ROS formation is a tightly balanced 
process, alterations during cancer therapy may be either tumor promoting (e.g. genetic 
instability) or inhibiting [150]. Exposure to HA alters the mitochondrial respiratory chain by 
increasing the COX4-2 expression in a HIF-1 mediated fashion. COX4 is a subunit of 
cytochrome oxidase and the alternative COX4-2 variant replaces COX4-1 during hypoxia, 
and so increasing the efficiency of electron transfer in complex IV under low oxygen 
concentrations [151]. This might prevent excessive ROS formation in cancer cells, but also, 
as in healthy muscle cells [152, 153], potentially protects organs and tissues from cytotoxic 
therapies. Furthermore, reduced expression of cytochrome P450 affects the metabolic 
clearance of drugs [154] and altered blood flow to organs might cause changes in drug 
distribution in comparison to lowlanders. It is also not clear if HA changes tumor perfusion 
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and thereby the tumor accessibility of the drugs. The response to tumor therapies at high 
altitude with and without therapy-associated anemia would be a very interesting area to focus 
future research efforts. 
3.3 Physical	Activity	
Regular physical activity, either by implementing exercise into daily life activities or by 
participating in sports, can be considered as an evolutionary based “wonder pill” for humans 
that has an overall beneficial impact on health throughout life [155, 156]. Fundamental 
scientific evidence demonstrates that regular physical activity can functionally strengthen and 
enhance almost every organic system of the human body (e.g. the cardiovascular, respiratory, 
musculoskeletal, metabolic, neurological, immune, and hematopoietic systems) [157]. 
Apparently, there is a genetically dependent [158] individual dose response to physical 
activity that needs to be considered in order to optimize health-related outcomes [159]. On 
the other hand, a sedentary life style is a well-known risk factor for various diseases and 
poorer outcomes [160]. In the context of cancer mortality, physical activity is an 
epidemiologically well-established preventive factor for frequent types of cancers and with a 
lesser base of evidence, this is true also for other cancers [161, 162]. Furthermore, it is an 
effective supportive therapeutic strategy during all different phases (pre, during, and post) of 
cancer therapy even with the potential to lower the risk of cancer reoccurrence [163, 164]. For 
example, a very recently performed meta-analysis of 26 individual studies found a 37% risk 
reduction of cancer-specific mortality in the most active patients suffering from either 
colorectal, breast, or prostate cancer when compared to the least active patients [165]. 
Considering the previously mentioned aspects of physical activity, it is obvious that the 
amount of exertion and exercise is a very crucial, if not one of the most important behavioral 
factors when investigating cancer incidence, prevalence and mortality among populations 
living at different altitudes. However, in line with a recent review statement by Burtscher et al. 
[48] there is currently a lack of available epidemiological data, which would allow a statistical 
factorial analysis to evaluate the impact of the level of physical activity, geographical location, 
and corresponding altitude on cancer-specific mortality. Of note, he recently reported a linear 
decline of age-standardized mortality rates for male colorectal cancer and female breast 
cancer with increasing altitude when analyzing data from the Austrian Mortality [166]. The 
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potentially higher exercise capacity of people living at altitude was proposed, among other 
factors, to be responsible for the observed lower cancer mortality rate [166]. Driven by the 
rising socio-economic burden of modern personalized drug-based cancer therapy [167] 
recent translational efforts across the spectrum from basic to clinical research are beginning 
to unravel the complex and multifactorial molecular mechanisms responsible for the overall 
beneficial effects of physical activity on cancer mortality [164]. Obviously, the primary target 
organs of exercise are the skeletal muscles and heart. Exercise-induced muscle tissue 
hypoxia may be a key stimulus, predominantly mediated via hypoxia inducible factors (HIFs) 
signaling cascades [168, 169]. This implicates a complex molecular crosstalk between the 
two stimuli of physical activity and altitude exposure, which may lead to an altered cellular 
response in people physically active at altitude. In fact, endurance athletes use various forms 
of altitude-training (e.g. live high, train high: LHTH) to improve exercise performance by 
combining both stimuli [170]. In contrast to popular belief, the skeletal musculature is not 
solely a motor organ but also a highly active endocrine organ that communicates mainly 
through the vascular circuitry with other body tissues via release of extracellular vesicles and 
secretory cytokines, known as myokines [171]. A recent preclinical study performed in five 
different tumor-bearing mouse models found that voluntary exercise on a running-wheel could 
reduce tumor incidence and growth by more than 60%, especially when applied four weeks 
before tumor implantation and then continued for the two weeks after tumor implantation [172]. 
In the same study the authors further reported that these beneficial effects were mainly driven 
by an epinephrine-dependent mobilization of natural killer cells into the blood stream and 
interleukin-6 (IL-6)-dependent targeting of these cells to tumors. Interestingly, IL-6 is also a 
myokine [173], which is known to be secreted from the skeletal muscle upon contraction and 
probably also hypoxia [174-177]. Another important cellular aspect of physical activity is the 
fact that exercise can increase the number of adult stem cells (ASCs) [178]. Considering the 
previously mentioned DeGregori hypothesis of cellular fitness and cancer evolution [47], an 
exercise-induced increase of healthy ASCs may not only boost tissue regeneration and 
rejuvenation, but also the anti-oncogenic potential of the corresponding tissue.  
To briefly summarize, there is compelling evidence from both animal and human studies that 
physical activity reduces cancer-specific mortality. However, due to the current lack of 
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available epidemiological data, no conclusions can be drawn about the impact of physical 
activity on altered cancer-specific mortality of populations living at different altitudes. 
Furthermore, the suggested molecular crosstalk between the two stimuli of exercise and 
altitude exposure further complicates the search for a mechanistic understanding. 
4 Conclusion	
In many cases, cancer mortality declines with increasing altitude, but the mechanisms that 
drive tumor suppression are unknown and, due to the complexity of HA adaption processes, 
difficult to identify. Exposure to HA causes multifactorial cellular, physiological and metabolic 
alterations that potentially have an impact on tumor mortality. HA and hypoxia induced 
mechanisms aim at coping with hypoxia and best adapting to HA. Many of these pathways 
are interconnected in a complex manner. Based on DeGregori’s hypothesis of adaptive 
oncogenesis [47], we suggest that adaptation may increase fitness of healthy cells to better 
compete with cancer cells within the same niche (Fig.1). In a simplified scheme, one might 
compare these cells with exercising humans where stress-stimuli increase the cell`s fitness 
level. As a consequence, it is possible that, instead of individual pathways, the sum of all (or 
some) adaptive processes results in reduced cancer mortality, which may complicate 
mechanistically studies. However, some feasible studies could shed some more light on this 
“black box”. The poor prognostic factor anemia of cancer with incidence, pathology, severity 
and response to treatment could usefully contribute to understanding cancer mortality at HA. 
The recording of physical activity would be desirable in order to compare the activity pattern 
of “highlander” and “lowlander” cancer patients in relation to mortality. Finally, the efficacy of 
drugs including their pharmacodynamics and pharmacokinetics needs to be addressed at HA. 
Drug metabolism is clearly altered in humans exposed to hypoxia and HA and it is 
fundamental to understand how patients respond to any kind of drug – including cancer 
therapeutics – in order to guarantee safety and efficacy. 
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Figure legend: 
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Figure 1: How high altitude exposure might influence cancer cells. 
Assuming that tumorigenesis is an evolutionary selection process, it requires cancer cells 
(violet) to compete with healthy cells (orange) within the same, resource-restricted niche. If 
cancer cells are able to successfully populate this niche mainly depends on the quality of the 
microenvironment (e.g. nutrition availability) and how effective healthy cells are able to 
compete against cancer cells. In other words, healthy cells with a high cellular fitness as well 
as an increased demand for nutrition are better competitors and thus impede more 
successfully the tumor development. Based on this assumption, we suggest a hypothesis for 
reduced cancer mortality at high altitude: At low altitude (normoxia) expanding tumors 
increase expression of HIFs that partially contribute to an elevated uptake of lipids, glucose 
and iron that are essential for tumor progression. Healthy cells in contrast display no increase 
in HIF-dependent gene expression at low altitude. With increasing altitude however, healthy 
cells experience a hypoxia-driven, partially HIF-dependent shift in cellular metabolism (similar 
to tumor cells at low altitude) that may lead to increased nutrition demand. With the activation 
of nutrition uptake and utilization pathways healthy cells are more competitive, and thus fitter, 
against cancer cells. Moreover, high altitude exposure leads to a reduction of glucose as well 
as lipids and potentially iron plasma levels. This suggests that in addition to higher uptake 
rates of healthy cells the general availability of resources is declining with increasing altitude 
resulting in unfavorably environmental conditions for tumor growth and thus in a reduction of 
cancer cell fitness. On top of that, physical activity (e.g. exercise), that is already tumor-
suppressive at low altitude may be boosted in combination with HA exposure. 
 
 
 
